Ken Keller, President & CEO of Daiichi Sankyo, discusses the company's shift to oncology, focusing on ADCs success, HER2-targeted therapies, and strategic partnerships. He emphasizes hiring passionate innovators, global drug access, and the future of cancer therapies

Ken Keller, Senior Executive at Daiichi Sankyo, shares the story of Daiichi Sankyo's leap into oncology with ADCs. He discusses the evolution of the ADC market, challenges faced in the transition, scaling a global oncology team, navigating internal challenges, embracing innovation, addressing employee resistance to change, and revolutionizing cancer treatment with ADCs.